uniQure also is eligible to receive an additional $25m milestone payment if 2024 net sales of etranacogene dezaparvovec-drbl exceed a pre-specified threshold. uniQure will retain the rights to all other royalties under its existing commercialisation and license agreement with CSL Behring, as well as contractual milestones totaling up to $1.5bn, including a $100m milestone for the first US product sale and a $75m milestone for the first product sale in one of five major European countries if achieved prior to July 2, 2023. The transaction is expected to close no later than 15 business days from signing.
Amsterdam-based uniQure NV led the multi-year development of etranacogene dezaparvovec-drbl and completed an exclusive global license and commercialization agreement with CSL Behring in May 2021. Etranacogene dezaparvovec-drbl HEis approved for the treatment of hemophilia B in the US, Europe and the United Kingdom. CSL Behring also is pursuing registration in additional countries.
uniQure expects the transaction will extend its cash runway into the second quarter of 2026, assuming receipt of the contractual milestone payment for the first sale of etranacogene dezaparvovec-drbl in the US.